Xie Y, Su N, Zhou W, et al. - Findings demonstrated a poor response to EGFR-TKI treatment, especially in terms of survival outcome, among lung adenocarcinoma (LUAD) patients with concomitant pulmonary tuberculosis (PTB).

• A total of 1,448 Chinese epidermal growth factor receptor (EGFR) mutant LUAD patients that received EGFR-TKI treatment were included, and were split into PTB and non-PTB groups.

• Following EGFR-TKIs treatment, higher objective response rate (58.14% vs 47.62%) and disease control rate (97.67% vs 85.71%) were observed in the non-PTB group vs in the PTB group, but there was no statistical difference.

• PTB group had significantly shorter median progression-free survival (7.47 months vs 11.77 months) as well as overall survival (13.00 months vs 20.00 months), relative to the non-PTB group.

• A significantly prolonged median progression-free survival and overall survival resulted with EGFR-TKIs treatment among patients without PTB who had 19Del mutation, or metastases sites less than 3, or receiving first-line EGFR-TKI.